Some genetic studies have shown a linkage between malignant hyperthermia susceptibility (MHS) and chromosome 19q or the skeletal muscle ryanodine receptor (RYR1) gene. Some types of MHS seem to be caused by an abnormality of calcium-induced calcium release (CICR). We analyzed the linkage of RYR 1 gene polymorphisms in Japanese MHS families and investigated the correlation between genetic evidence of RYR1 gene mutations and an accelerated rate of CICR. We studied 63 subjects who were referred to our institute for investigation of MHS. CICR rates were measured by the skinned fiber method in 23 subjects. DNA samples were collected from 63 individuals belonging to 22 unrelated families. Restriction fragment length polymorphism (RFLP) analyse...
SummaryMalignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggere...
Aside from the in vitro contracture test, genetic screening for causative RYR1 mutations is the esta...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggered in ge...
Some genetic studies have shown a linkage between malignant hyperthermia susceptibility (MHS) and ch...
Malignant Hyperthermia (MH) is an inherited disorder of skeletal muscle in which an abnormality in t...
Background: Malignant hyperthermia (MH) is a disorder of calcium homeostasis in skeletal muscle trig...
Malignant hyperthermia (MH) is an autosomal dominant disorder characterized by abnormal calcium home...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle which results from anae...
International audienceMalignant hyperthermia susceptibility (MHS) is a subclinical pharmacogenetic d...
Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disease, triggered by inhalative...
Malignant hyperthermia (MH) is an anaesthetic complication that causes an abnormal hypermetabolic st...
: Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder of skeletal muscle c...
Malignant hyperthermia (MH) is an autosomal dominant disorder which is potentially lethal in suscept...
Malignant hyperthermia (MH) is a rare pharmacogenetic disorder in humans caused by inhalational gene...
Study of the genetics of the malignant hyperthermia syndrome began in families in which both maligna...
SummaryMalignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggere...
Aside from the in vitro contracture test, genetic screening for causative RYR1 mutations is the esta...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggered in ge...
Some genetic studies have shown a linkage between malignant hyperthermia susceptibility (MHS) and ch...
Malignant Hyperthermia (MH) is an inherited disorder of skeletal muscle in which an abnormality in t...
Background: Malignant hyperthermia (MH) is a disorder of calcium homeostasis in skeletal muscle trig...
Malignant hyperthermia (MH) is an autosomal dominant disorder characterized by abnormal calcium home...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle which results from anae...
International audienceMalignant hyperthermia susceptibility (MHS) is a subclinical pharmacogenetic d...
Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disease, triggered by inhalative...
Malignant hyperthermia (MH) is an anaesthetic complication that causes an abnormal hypermetabolic st...
: Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder of skeletal muscle c...
Malignant hyperthermia (MH) is an autosomal dominant disorder which is potentially lethal in suscept...
Malignant hyperthermia (MH) is a rare pharmacogenetic disorder in humans caused by inhalational gene...
Study of the genetics of the malignant hyperthermia syndrome began in families in which both maligna...
SummaryMalignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggere...
Aside from the in vitro contracture test, genetic screening for causative RYR1 mutations is the esta...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggered in ge...